<p><strong>德克萨斯州达拉斯，2025 年 12 月 19 日（全球新闻通讯）--</strong> Mangoceuticals, Inc.（纳斯达克代码：MGRX）（“公司”）是一家专注于通过安全的远程医疗平台开发、营销和销售各种健康和保健产品的公司，旗下品牌包括 MangoRx 和 PeachesRx。今天，公司宣布完成其之前宣布的注册直接发行和与机构投资者的同时私募。公司在注册直接发行中发行了普通股和预融资认股权证。在同时的私募中，公司还向同一投资者发行了投资者认股权证。两项交易的总毛收入约为 250 万美元。交易于 2025 年 12 月 19 日完成。交易价格符合纳斯达克规则的市场价格。</p>
<p>交易包括销售 1,930,502 个普通单位（或预融资单位），每个单位包括（i）一（1）股普通股或一（1）个预融资认股权证，以及（ii）一个（1）个 PIPE 普通认股权证，每个认股权证可购买一（1）股普通股，行使价格为 1.4245 美元。每个普通单位的发行价格为 1.295 美元（或每个预融资单位为 1.29499 美元，等于发行中每个普通单位的发行价格减去每个预融资认股权证的行使价格 0.00001 美元）。预融资认股权证可立即行使，并可在完全行使之前的任何时间行使。对于在发行中销售的每个预融资单位，发行中的普通单位数量将按一对一的比例减少。</p>
<p>公司总毛收入约为 250 万美元。交易于 2025 年 12 月 19 日完成。公司预计将利用发行的净收益以及现有现金用于一般企业用途和营运资金。</p>
<p><strong>Aegis Capital Corp.担任此次发行的独家配售代理。Lucosky Brookman LLP 担任公司的法律顾问。Kaufman &amp; Canoles, P.C.担任 Aegis Capital Corp.的法律顾问。</strong></p>
<p>此次注册直接发行是根据之前向美国证券交易委员会（SEC）提交并于 2025 年 6 月 24 日获得 SEC 批准的有效货架注册声明（编号 333-288039）进行的。最终的招股说明书补充及相关招股说明书将提交给 SEC，并将在 SEC 网站 www.sec.gov 上提供。最终招股说明书补充及相关招股说明书的电子副本可在可用时通过联系 Aegis Capital Corp.，注意：承销部，1345 Avenue of the Americas，27 楼，纽约，NY 10105，电子邮件 syndicate@aegiscap.com，或电话 +1（212）813-1010 获取。</p>
<p>私募中证券的发行和销售是在不涉及公开发行的交易中进行的，并且未根据《1933 年证券法》（修订版）（“证券法”）或适用的州证券法进行注册。因此，除非根据有效的注册声明或适用的证券法注册要求的豁免，否则这些证券不得在美国重新发行或转售。证券仅向合格投资者提供。根据与投资者的注册权协议，公司已同意向 SEC 提交一份或多份注册声明，涵盖普通股的转售以及在行使预融资认股权证和认股权证时可发行的股份。</p>
<p>本新闻稿不构成出售要约或购买要约的征求，也不应在任何州或司法管辖区进行这些证券的销售，除非在该州或司法管辖区的证券法下注册或合格之前，这种要约、征求或销售是非法的。</p>
<p><strong>关于 Mangoceuticals, Inc.</strong></p>
<p>MangoRx 专注于通过安全的远程医疗平台开发各种男性健康和保健产品及服务。迄今为止，公司已将男性健康远程医疗服务和产品确定为一个增长领域，特别是与勃起功能障碍（ED）、毛发生长、激素替代疗法和体重管理相关的领域。感兴趣的消费者可以使用 MangoRx 的远程医疗平台获得顺畅的体验。处方请求将由医生审核，如果获得批准，将通过 MangoRx 的合作药房进行履行，并直接送到患者家门口。要了解更多关于 MangoRx 的使命和其他产品的信息，请访问 www.MangoRx.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>上述材料可能包含根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条（均已修订）所定义的 “前瞻性声明”。前瞻性声明包括所有不单纯涉及历史或当前事实的声明，包括但不限于关于公司的产品开发和商业前景的声明，并且可以通过使用 “可能”、“将”、“期望”、“项目”、“估计”、“预期”、“计划”、“相信”、“潜在”、“应该”、“继续” 或这些词的否定形式或其他可比词汇来识别。前瞻性声明并不保证未来的行动或表现。这些前瞻性声明基于公司当前可获得的信息及其当前计划或预期，并受到可能显著影响当前计划的多种风险和不确定性的制约。如果这些风险或不确定性中的一个或多个实现，或基础假设被证明不正确，实际结果可能与预期、相信、估计、期望、意图或计划的结果有显著差异。尽管公司相信前瞻性声明中反映的期望是合理的，但公司无法保证未来的结果、表现或成就。除非适用法律（包括美国的证券法）要求，否则公司不打算更新任何前瞻性声明以使这些声明与实际结果相符。</p>
<p>投资者关系</p>
<p>Mangoceuticals 投资者关系</p>
<p>电子邮件：investors@mangorx.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05URTVOaU0zTXpNd056azFJelV3TURFeE5qRXdOUT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05URTVOaU0zTXpNd056azFJelV3TURFeE5qRXdOUT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWJkNDNmYzItZTljYy00MmFmLTg4ZDItNzljMmZjMWQwZTM1LTUwMDExNjEwNS0yMDI1LTEyLTE5LWVu/tiny/Mangoceuticals-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWJkNDNmYzItZTljYy00MmFmLTg4ZDItNzljMmZjMWQwZTM1LTUwMDExNjEwNS0yMDI1LTEyLTE5LWVu/tiny/Mangoceuticals-Inc-.png"/></p>

MGRX

<p>Mangoceuticals, Inc.（纳斯达克代码：MGRX）宣布完成一项 250 万美元的注册直接发行和与机构投资者的同时私募。该公司发行了普通股和预先融资的认股权证，交易于 2025 年 12 月 19 日完成。所得款项将用于一般企业用途和营运资金。Aegis Capital Corp. 担任独家配售代理。此次发行是在向美国证券交易委员会（SEC）提交的有效的货架注册声明下进行的</p>

<p><strong>DALLAS, TX, Dec. 19, 2025 (GLOBE NEWSWIRE) --</strong> Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced the closing of its previously announced registered direct offering and concurrent private placement with institutional investors. The Company issued shares of Common Stock and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also issued to the same investors investor warrants. Aggregate gross proceeds to the Company from both transactions were approximately $2.5 million. The transactions closed on December 19, 2025. The transactions were priced at the market under Nasdaq rules.</p>
<div class="lb-trans"><p><strong>德克萨斯州达拉斯，2025 年 12 月 19 日（全球新闻通讯）--</strong> Mangoceuticals, Inc.（纳斯达克代码：MGRX）（“公司”）是一家专注于通过安全的远程医疗平台开发、营销和销售各种健康和保健产品的公司，旗下品牌包括 MangoRx 和 PeachesRx。今天，公司宣布完成其之前宣布的注册直接发行和与机构投资者的同时私募。公司在注册直接发行中发行了普通股和预融资认股权证。在同时的私募中，公司还向同一投资者发行了投资者认股权证。两项交易的总毛收入约为 250 万美元。交易于 2025 年 12 月 19 日完成。交易价格符合纳斯达克规则的市场价格。</p>
</div><p>The transactions consisted of the sale of 1,930,502 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant and (ii) one (1) PIPE Common Warrant to purchase one (1) share of Common Stock per warrant at an exercise price of $1.4245. The offering price per Common Unit is $1.295 (or $1.29499 for each Pre-Funded Unit, which is equal to the offering price per Common Unit sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Unit sold in the offering, the number of Common Units in the offering will be decreased on a one-for-one basis.</p>
<div class="lb-trans"><p>交易包括销售 1,930,502 个普通单位（或预融资单位），每个单位包括（i）一（1）股普通股或一（1）个预融资认股权证，以及（ii）一个（1）个 PIPE 普通认股权证，每个认股权证可购买一（1）股普通股，行使价格为 1.4245 美元。每个普通单位的发行价格为 1.295 美元（或每个预融资单位为 1.29499 美元，等于发行中每个普通单位的发行价格减去每个预融资认股权证的行使价格 0.00001 美元）。预融资认股权证可立即行使，并可在完全行使之前的任何时间行使。对于在发行中销售的每个预融资单位，发行中的普通单位数量将按一对一的比例减少。</p>
</div><p>Aggregate gross proceeds to the Company were approximately $2.5 million. The transaction closed on December 19, 2025. The Company expects to use the net proceeds from the offerings, together with its existing cash, for general corporate purposes and working capital.</p>
<div class="lb-trans"><p>公司总毛收入约为 250 万美元。交易于 2025 年 12 月 19 日完成。公司预计将利用发行的净收益以及现有现金用于一般企业用途和营运资金。</p>
</div><p><strong>Aegis Capital Corp. acted as exclusive placement agent for the offerings. Lucosky Brookman LLP acted as counsel to the Company. Kaufman &amp; Canoles, P.C. acted as counsel to Aegis Capital Corp.</strong></p>
<div class="lb-trans"><p><strong>Aegis Capital Corp.担任此次发行的独家配售代理。Lucosky Brookman LLP 担任公司的法律顾问。Kaufman &amp; Canoles, P.C.担任 Aegis Capital Corp.的法律顾问。</strong></p>
</div><p>The registered direct offering was being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-288039) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on June 24, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.</p>
<div class="lb-trans"><p>此次注册直接发行是根据之前向美国证券交易委员会（SEC）提交并于 2025 年 6 月 24 日获得 SEC 批准的有效货架注册声明（编号 333-288039）进行的。最终的招股说明书补充及相关招股说明书将提交给 SEC，并将在 SEC 网站 www.sec.gov 上提供。最终招股说明书补充及相关招股说明书的电子副本可在可用时通过联系 Aegis Capital Corp.，注意：承销部，1345 Avenue of the Americas，27 楼，纽约，NY 10105，电子邮件 syndicate@aegiscap.com，或电话 +1（212）813-1010 获取。</p>
</div><p>The offer and sale of the securities in the private placement were made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the SEC covering the resale of the Common Stock and the Shares issuable upon exercise of the pre-funded warrants and warrants.</p>
<div class="lb-trans"><p>私募中证券的发行和销售是在不涉及公开发行的交易中进行的，并且未根据《1933 年证券法》（修订版）（“证券法”）或适用的州证券法进行注册。因此，除非根据有效的注册声明或适用的证券法注册要求的豁免，否则这些证券不得在美国重新发行或转售。证券仅向合格投资者提供。根据与投资者的注册权协议，公司已同意向 SEC 提交一份或多份注册声明，涵盖普通股的转售以及在行使预融资认股权证和认股权证时可发行的股份。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售要约或购买要约的征求，也不应在任何州或司法管辖区进行这些证券的销售，除非在该州或司法管辖区的证券法下注册或合格之前，这种要约、征求或销售是非法的。</p>
</div><p><strong>About Mangoceuticals, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Mangoceuticals, Inc.</strong></p>
</div><p>MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com.</p>
<div class="lb-trans"><p>MangoRx 专注于通过安全的远程医疗平台开发各种男性健康和保健产品及服务。迄今为止，公司已将男性健康远程医疗服务和产品确定为一个增长领域，特别是与勃起功能障碍（ED）、毛发生长、激素替代疗法和体重管理相关的领域。感兴趣的消费者可以使用 MangoRx 的远程医疗平台获得顺畅的体验。处方请求将由医生审核，如果获得批准，将通过 MangoRx 的合作药房进行履行，并直接送到患者家门口。要了解更多关于 MangoRx 的使命和其他产品的信息，请访问 www.MangoRx.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.</p>
<div class="lb-trans"><p>上述材料可能包含根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条（均已修订）所定义的 “前瞻性声明”。前瞻性声明包括所有不单纯涉及历史或当前事实的声明，包括但不限于关于公司的产品开发和商业前景的声明，并且可以通过使用 “可能”、“将”、“期望”、“项目”、“估计”、“预期”、“计划”、“相信”、“潜在”、“应该”、“继续” 或这些词的否定形式或其他可比词汇来识别。前瞻性声明并不保证未来的行动或表现。这些前瞻性声明基于公司当前可获得的信息及其当前计划或预期，并受到可能显著影响当前计划的多种风险和不确定性的制约。如果这些风险或不确定性中的一个或多个实现，或基础假设被证明不正确，实际结果可能与预期、相信、估计、期望、意图或计划的结果有显著差异。尽管公司相信前瞻性声明中反映的期望是合理的，但公司无法保证未来的结果、表现或成就。除非适用法律（包括美国的证券法）要求，否则公司不打算更新任何前瞻性声明以使这些声明与实际结果相符。</p>
</div><p>FOR INVESTOR RELATIONS</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>Mangoceuticals Investor Relations</p>
<div class="lb-trans"><p>Mangoceuticals 投资者关系</p>
</div><p>Email: investors@mangorx.com</p>
<div class="lb-trans"><p>电子邮件：investors@mangorx.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05URTVOaU0zTXpNd056azFJelV3TURFeE5qRXdOUT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwNTE5NiM3MzMwNzk1IzUwMDExNjEwNQ=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWJkNDNmYzItZTljYy00MmFmLTg4ZDItNzljMmZjMWQwZTM1LTUwMDExNjEwNS0yMDI1LTEyLTE5LWVu/tiny/Mangoceuticals-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/YWJkNDNmYzItZTljYy00MmFmLTg4ZDItNzljMmZjMWQwZTM1LTUwMDExNjEwNS0yMDI1LTEyLTE5LWVu/tiny/Mangoceuticals-Inc-.png"/></p>

Mangoceuticals, Inc. 宣布完成 250 万美元的注册直接发行和私募配售 | MGRX 股票新闻